Structured evidence table for Amla Lipid Profile Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Amla Lipid Profile Randomized Trial | Background Dyslipidemia, marked by abnormal lipid levels, significantly increases the risk of cardiovascular diseases. | 4 | Jagalurappa K (2025) | Effect of <i>Emblica officinalis</i> (Amla) Extract Versus Exercise on Lipid Levels in Participants With Abnormal Lipid Levels: An Open-Label Clinical Study. |
| Amla Lipid Profile Randomized Trial | Effective management of these lipid abnormalities is essential for reducing cardiovascular risk. | 4 | Jagalurappa K (2025) | Effect of <i>Emblica officinalis</i> (Amla) Extract Versus Exercise on Lipid Levels in Participants With Abnormal Lipid Levels: An Open-Label Clinical Study. |
| Amla Lipid Profile Randomized Trial | Results Amla extract over a period of 90 days significantly reduced triglyceride ( P = 0.007), total cholesterol ( P P = 0.006), VLDL ( P = 0.014), and AIP ( P P = 0.967) and fasting blood sugar ( P = 1.00). | 4 | Jagalurappa K (2025) | Effect of <i>Emblica officinalis</i> (Amla) Extract Versus Exercise on Lipid Levels in Participants With Abnormal Lipid Levels: An Open-Label Clinical Study. |
| Amla Lipid Profile Randomized Trial | In addition, high blood plasma triglyceride (TG) levels add another independent risk factor for the development of coronary artery disease (CAD) and cardiovascular events (;;). | 4 | Hermans Michel P. (2023) | The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla ( Emblica officinalis ), walnut ( Juglans regia ), olive ( Olea europaea ) and red yeast rice ( Monascus purpureus ) powder: Reduction in circulatory low-density lipoprotein-cholesterol (LDL-C) and remnant cholesterol (RC) levels in patients with hypercholesterolemia |
| Amla Lipid Profile Randomized Trial | Among the key risk factors of secondary hypercholesterolemia are excessive consumption of saturated fats, trans-fatty acids, cholesterol-rich diets, and a sedentary lifestyle. | 4 | Hermans Michel P. (2023) | The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla ( Emblica officinalis ), walnut ( Juglans regia ), olive ( Olea europaea ) and red yeast rice ( Monascus purpureus ) powder: Reduction in circulatory low-density lipoprotein-cholesterol (LDL-C) and remnant cholesterol (RC) levels in patients with hypercholesterolemia |
| Amla Lipid Profile Randomized Trial | Among these medications, statins have proven to be most effective in reducing LDL-C levels and decreasing ASCVD risk by 15%–37%, and they are recommended as a first-line therapy for the primary and secondary prevention of ASCVD. | 4 | Hermans Michel P. (2023) | The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla ( Emblica officinalis ), walnut ( Juglans regia ), olive ( Olea europaea ) and red yeast rice ( Monascus purpureus ) powder: Reduction in circulatory low-density lipoprotein-cholesterol (LDL-C) and remnant cholesterol (RC) levels in patients with hypercholesterolemia |
| Amla Lipid Profile Randomized Trial | Hypercholesterolemia is generally asymptomatic until substantial atherosclerosis has developed. | 4 | Hermans Michel P. (2023) | The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla ( Emblica officinalis ), walnut ( Juglans regia ), olive ( Olea europaea ) and red yeast rice ( Monascus purpureus ) powder: Reduction in circulatory low-density lipoprotein-cholesterol (LDL-C) and remnant cholesterol (RC) levels in patients with hypercholesterolemia |
Source documents